Pds Biotechnology Corp 8-K Filing
Ticker: PDSB · Form: 8-K · Filed: Mar 30, 2026 · CIK: 0001472091
| Field | Detail |
|---|---|
| Company | Pds Biotechnology Corp (PDSB) |
| Form Type | 8-K |
| Filed Date | Mar 30, 2026 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00033 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Pds Biotechnology Corp (ticker: PDSB) to the SEC on Mar 30, 2026.
What are the key financial figures in this filing?
Key dollar amounts include: $0.00033 (h registered Common Stock, par value $0.00033 per share PDSB The Nasdaq Stock Mar).
How long is this filing?
Pds Biotechnology Corp's 8-K filing is 2 pages with approximately 550 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 550 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2026-03-30 07:05:29
Key Financial Figures
- $0.00033 — h registered Common Stock, par value $0.00033 per share PDSB The Nasdaq Stock Mar
Filing Documents
- ef20069202_8k.htm (8-K) — 28KB
- ef20069202_ex99-1.htm (EX-99.1) — 76KB
- image00001.jpg (GRAPHIC) — 263KB
- 0001140361-26-011862.txt ( ) — 600KB
- pdsb-20260330.xsd (EX-101.SCH) — 4KB
- pdsb-20260330_lab.xml (EX-101.LAB) — 21KB
- pdsb-20260330_pre.xml (EX-101.PRE) — 16KB
- ef20069202_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operation and Financial Condition. On March 30, 2026, PDS Biotechnology Corporation (the "Company") issued a press release announcing a business update and its financial results for the year ended December 31, 2025. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information set forth in this Current Report on Form 8-K (including Exhibit 99.1) is deemed to be "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of the section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated March 30, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PDS BIOTECHNOLOGY CORPORATION Date: March 30, 2026 By: /s/ Frank Bedu-Addo, Ph.D. Name: Frank Bedu-Addo, Ph.D. Title: President and Chief Executive Officer